Our vaccine technology is based on safe and effective enveloped virus-like particles (VLPs). The manufacturing involves our proprietary highly productive cell line, and high yield of enveloped nanoparticles is achieved. Our VLP production platform allows rapid and adaptable vaccine development. We are addressing unmet need for a broad, long-lasting mucosal vaccine for SARS-CoV-2 virus. In addition, annual epidemics of highly lethal Nipah virus (NiV) pose a severe global threat, for which there is no available vaccine.